Abstract

Objective: To determine the association between circulating levels of omentin-1, a novel adipocytokine and coronary artery disease in the local population of Karachi.
 Methods: A total of 350 subjects were included in the study from June 2016 to December 2016. About 250 patients, who had undergone coronary angiography in Karachi Institute of Heart Disease (KIHD) and Civil Hospital Karachi (CHK) and 100 served as healthy controls. Serum concentrations of omentin-1 were measured by using enzyme-linked immunosorbent assay (ELISA) at Dr. A Q. Khan In- stitute of Biotechnology (KIBGE) and lipid profile, fasting blood sugar were done at KIHD lab. Coro- nary artery disease (CAD) and cardiovascular disease risk factors were evaluated by using the software SPSS 16. Independent sample t-test and chi-square tests were used to analyse the clinical and demographic characteristics of data. Simple logistic regression and then multivariate analysis were performed to evaluate correlations between CAD and all other parameters. P value less than
 0.05 was considered statistically significant. This research is part of MPhil thesis and there are two research papers; (1) Serum Omentin-1 Levels with CAD (current paper) and (2) genetic polymor- phism/mutation of omentin-1 gene in developing CAD. Latter is also in process of publication.
 Results: Serum omentin-1 levels were found to be lower in patients with CAD as compared to controls (456 ± 99 vs 739 ± 72; p<0.01). Serum concentration of omentin-1 was negatively correlated with body waist circumference (39.95 ± 3.1 vs 30.95 ± 3.7; p< 0.05), whereas positively associated with serum High Density Lipoprotein (HDL) levels (25.9 ± 6.2 vs 42.3 ± 10; p< 0.05). Moreover, multiple logistic regression analysis demonstrated that serum omentin-1 concentration was indepen- dently correlated with CAD.
 Conclusion: The current study has suggested that serum concentrations of omentin-1 might be re- lated to pathogenesis and progress of CAD.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.